A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer and Hot Flashes, sponsored by Bayer. Active, not recruiting at 102 sites in 16 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.
Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 2nd largest by enrollment, is one of 5 that started in 2022, is one of 4 in phase 3, and was the 12th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4
First in 2016; this study’s year is marked. 5 started in 2022.
This study's enrollment of 474 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 64 across the 13 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 1 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 4th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 17th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing elinzanetant in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.
VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.
It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.
The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.
The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.
To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.
To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.
The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.
All participants will continue taking the anti-cancer therapy they have been using when entering the study.
Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.
Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another up to 3.5 years.
During the study, the participants will:
The doctors and their study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants' health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women experiencing vasomotor symptoms (VMS) caused by endocrine therapy that they are expected to use for the duration of the study
Women must have
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 120 mg elinzanetant orally once daily.
Drug: Elinzanetant (BAY3427080)
Participants will receive matching placebo orally once daily for 12 weeks, followed by 120 mg elinzanetant orally once daily
Drug: Elinzanetant (BAY3427080) · Drug: Placebo
120 mg elinzanetant orally once daily
Matching placebo orally once daily
Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
Time frame: Baseline to Week 4
Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
Time frame: Baseline to Week 12
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).
In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).
Time frame: Baseline to Week 4
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).
Time frame: Baseline to Week 12
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
Time frame: Baseline to Week 1
Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
Time frame: Baseline to Week 50
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total Score From Baseline to Week 12
The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.
Time frame: Baseline to Week 12
Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12
The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If participants select yes, participants rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother. For a MENQOL total score, the aggregated mean of the mean domain scores is calculated.
Time frame: Baseline to Week 12
The study was conducted at 97 study centers, predominantly in Europe and at several centers in Canada, Israel, Kazakhstan and United Kingdom starting 14-Oct-2022 (first participant first visit), reaching primary completion on 29-Jan-2024.
| Milestone | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Started | 316 | 158 |
| Completed | 262 | 133 |
| Not completed | 54 | 25 |
| Withdrew: Adverse event | 15 | 7 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 14 | 4 |
| Withdrew: Miscellaneous | 3 | 6 |
| Withdrew: Did not complete study treatment but completed post-treatment phase/follow-up | 19 | 8 |
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
| hot flashes per day | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 11.41 ± 6.89 | 11.52 ± 6.43 |
| Change from Baseline Week 4 | -6.51 ± 6.13 | -3.04 ± 5.04 |
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
| hot flashes per day | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 11.41 ± 6.89 | 11.52 ± 6.43 |
| Change from Baseline week 12 | -7.76 ± 6.17 | -4.20 ± 6.06 |
In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).
| score*hot flashes/total of hot flashes | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 2.49 ± 0.24 | 2.49 ± 0.22 |
| Change from Baseline week 4 | -0.73 ± 0.60 | -0.43 ± 0.43 |
In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).
| score*hot flashes/total of hot flashes | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 2.49 ± 0.24 | 2.49 ± 0.22 |
| Change from Baseline week 12 | -0.98 ± 0.72 | -0.53 ± 0.60 |
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
| hot flashes per day | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 11.41 ± 6.89 | 11.52 ± 6.43 |
| Change from baseline week 1 | -4.04 ± 5.11 | -1.76 ± 3.83 |
Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.
| hot flashes per day | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 11.41 ± 6.89 | 11.52 ± 6.43 |
| Change from baseline to Week 1 | -4.04 ± 5.11 | -1.76 ± 3.83 |
| Change from baseline to Week 2 | -5.55 ± 5.88 | -2.78 ± 4.31 |
| Change from baseline to Week 3 | -6.19 ± 5.94 | -2.96 ± 4.82 |
| Change from baseline to Week 4 | -6.51 ± 6.13 | -3.04 ± 5.04 |
| Change from baseline to Week 5 | -6.84 ± 5.92 | -3.35 ± 5.06 |
| Change from baseline to Week 6 | -7.04 ± 6.20 | -3.69 ± 5.37 |
| Change from baseline to Week 7 | -7.32 ± 6.05 | -3.96 ± 5.60 |
| Change from baseline to Week 8 | -7.45 ± 6.25 | -4.02 ± 5.53 |
| Change from baseline to Week 9 | -7.49 ± 6.29 | -4.00 ± 5.64 |
| Change from baseline to Week 10 | -7.48 ± 6.03 | -3.88 ± 5.82 |
| Change from baseline to Week 11 | -7.74 ± 6.16 | -4.08 ± 5.94 |
| Change from baseline to Week 12 | -7.76 ± 6.17 | -4.20 ± 6.06 |
| Change from baseline to Week 25 | -8.98 ± 6.12 | -9.60 ± 6.04 |
| Change from baseline to Week 26 | -8.93 ± 6.13 | -9.55 ± 6.14 |
| Change from baseline to Week 35 | -9.05 ± 6.16 | -9.30 ± 6.23 |
| Change from baseline to Week 36 | -8.94 ± 6.15 | -9.13 ± 6.25 |
| Change from baseline to Week 49 | -8.77 ± 5.89 | -9.02 ± 6.17 |
| Change from baseline to Week 50 | -8.72 ± 6.22 | -8.90 ± 6.01 |
The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.
| T-Score | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 60.60 ± 6.33 | 60.74 ± 6.80 |
| Change from Baseline week 12 | -10.55 ± 8.20 | -4.06 ± 7.35 |
The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If participants select yes, participants rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother. For a MENQOL total score, the aggregated mean of the mean domain scores is calculated.
| Scores on a scale | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) |
|---|---|---|
| Baseline | 4.82 ± 1.17 | 4.77 ± 1.25 |
| Change from Baseline week 12 | -1.30 ± 1.11 | -0.53 ± 1.15 |
Collected over From signing the ICF through study complition, approximately 14 months. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elinzanetant 120mg Week 1-12 | 0/315 (0%) | 8/315 (2.5%) | 145/315 (46%) |
| Placebo Week 1-12 | 0/158 (0%) | 1/158 (0.6%) | 61/158 (38.6%) |
| Elinzanetant 120mg Week 13-26 | 0/294 (0%) | 8/294 (2.7%) | 72/294 (24.5%) |
| Placebo - Elinzanetant 120mg Week 13-26 | 0/150 (0%) | 4/150 (2.7%) | 38/150 (25.3%) |
| Elinzanetant 120mg Week 1-26 | 0/465 (0%) | 18/465 (3.9%) | 211/465 (45.4%) |
| Elinzanetant 120mg Week 27-52 | 0/409 (0%) | 18/409 (4.4%) | 73/409 (17.8%) |
| Elinzanetant 120mg Week 1-52 | 0/465 (0%) | 33/465 (7.1%) | 241/465 (51.8%) |
| Event | Elinzanetant 120mg Week 1-12 | Placebo Week 1-12 | Elinzanetant 120mg Week 13-26 | Placebo - Elinzanetant 120mg Week 13-26 | Elinzanetant 120mg Week 1-26 | Elinzanetant 120mg Week 27-52 | Elinzanetant 120mg Week 1-52 |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/315 | 0/158 | 0/294 | 1/150 | 1/465 | 0/409 | 1/465 |
| ConcussionInjury, poisoning and procedural complications | 0/315 | 0/158 | 0/294 | 1/150 | 1/465 | 0/409 | 1/465 |
| HypokalaemiaMetabolism and nutrition disorders | 0/315 | 0/158 | 0/294 | 1/150 | 1/465 | 0/409 | 1/465 |
| Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/315 | 0/158 | 0/294 | 1/150 | 1/465 | 0/409 | 1/465 |
| Ligament operationSurgical and medical procedures | 0/315 | 1/158 | 0/294 | 0/150 | 0/465 | 0/409 | 0/465 |
| Uterine polypReproductive system and breast disorders | 0/315 | 0/158 | 0/294 | 0/150 | 0/465 | 2/409 | 2/465 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/315 | 0/158 | 1/294 | 0/150 | 2/465 | 0/409 | 2/465 |
| Breast reconstructionSurgical and medical procedures | 1/315 | 0/158 | 0/294 | 0/150 | 1/465 | 1/409 | 2/465 |
| CataractEye disorders | 0/315 | 0/158 | 1/294 | 0/150 | 1/465 | 1/409 | 1/465 |
| Bile duct stoneHepatobiliary disorders | 0/315 | 0/158 | 1/294 | 0/150 | 1/465 | 0/409 | 1/465 |
| Event | Elinzanetant 120mg Week 1-12 | Placebo Week 1-12 | Elinzanetant 120mg Week 13-26 | Placebo - Elinzanetant 120mg Week 13-26 | Elinzanetant 120mg Week 1-26 | Elinzanetant 120mg Week 27-52 | Elinzanetant 120mg Week 1-52 |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 30/315 | 20/158 | 13/294 | 7/150 | 48/465 | 11/409 | 56/465 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/315 | 10/158 | 19/294 | 6/150 | 42/465 | 15/409 | 52/465 |
| SomnolenceNervous system disorders | 34/315 | 6/158 | 4/294 | 5/150 | 42/465 | 1/409 | 42/465 |
| FatigueGeneral disorders | 30/315 | 8/158 | 7/294 | 5/150 | 41/465 | 3/409 | 43/465 |
| Depression rating scale score increasedInvestigations | 21/315 | 13/158 | 1/294 | 0/150 | 22/465 | 2/409 | 26/465 |
| NasopharyngitisInfections and infestations | 12/315 | 5/158 | 9/294 | 8/150 | 28/465 | 9/409 | 37/465 |
| DiarrhoeaGastrointestinal disorders | 16/315 | 3/158 | 6/294 | 4/150 | 25/465 | 7/409 | 32/465 |
| COVID-19Infections and infestations | 4/315 | 4/158 | 9/294 | 4/150 | 17/465 | 13/409 | 32/465 |
| NauseaGastrointestinal disorders | 19/315 | 10/158 | 6/294 | 5/150 | 28/465 | 3/409 | 29/465 |
| Back painMusculoskeletal and connective tissue disorders | 10/315 | 7/158 | 5/294 | 2/150 | 16/465 | 14/409 | 29/465 |
| Age, Continuous(years) | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) | Total |
|---|---|---|---|
| Mean | 50.8 ± 7.5 | 51.5 ± 6.7 | 51.0 ± 7.3 |
| Sex: Female, Male(Participants) | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) | Total |
|---|---|---|---|
| Female | 316 | 158 | 474 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Elinzanetant (BAY3427080) | Placebo - Elinzanetant (BAY3427080) | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 5 | 12 |
| Not Hispanic or Latino | 289 | 143 | 432 |
| Unknown or Not Reported | 20 | 10 | 30 |
Showing the first 100 of 102 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Oct 2022 to primary completion in Jan 2024, 15 months.
Results were first posted in Oct 2025, 1 year 9 months after primary completion. A results delay was requested in Jan 2025.
Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant